Betsy Hanna
Chief Executive Officer
|
Betsy Hanna is a healthcare and biotech leader. Most recently she was Clinical Genomics’ chief commercial officer with responsibility for developing and executing go-to-market strategies. Ms. Hanna has two decades of healthcare industry experience including strategic marketing, U.S. and international sales management, and product launch. She joined Clinical Genomics from Origin, Inc., a clinical-stage biotech company where she was the president and chief operating officer. Prior to Origin, Ms. Hanna had increasing responsibility during eight years at Johnson & Johnson. At J&J diagnostics, she was vice president, strategic marketing and led the global launch of two instrument platforms. At J&J diagnostics, Hanna also served as vice president Europe, Mideast and Africa and, for J&J Vision Care, was vice president of strategic marketing and a member of the global management board. Ms. Hanna has a BS in Chemical Engineering from the University of Illinois and an MBA from Harvard Business School.
|
Laurie Huard
Chief Operating Officer
|
Ms. Huard has more than thirty years of experience in laboratory operations and lab informatics with a range of laboratories. Laurie previously served as Vice President of Operations at Helomics, Inc., a molecular diagnostics company, as a Laboratory Director for a large integrated hospital laboratory, and as a Laboratory Information Systems Manager. In addition, she has operated a lab informatics consulting practice for over ten years and has worked with numerous clients ranging from a nationally-recognized academic medical system laboratory (where she oversaw the implementation of a new LIS system) to large and small independent laboratory companies. She has extensive experience in all aspects of laboratory operations and lab informatics, including the selection, implementation and operation of a number of lab IT platforms in various clinical environments including clinical chemistry, microbiology, anatomic pathology and molecular diagnostics. Ms. Huard has a B.S. from Louisiana Tech University and an M.A. from Georgetown University.
|
Lawrence LaPointe, PhD
Chief Innovation Officer
|
Larry LaPointe, PhD, has more than two decades building healthcare companies to transform cancer testing, including most recently as co-founder of Clinical Genomics. He previously served as CTO and general manager of Enterix Inc, a cancer screening company he also co-founded. Dr. LaPointe is a well-published research scientist and holds numerous patents in biomarker discovery, cancer detection and molecular diagnostics. He has a BS in Biology from Florida State University and a PhD in Bioinformatics from Flinders University, Australia.
|
Roger Moody
Chief Financial Officer
|
Roger Moody brings to Clinical Genomics a proven track record in leading financial operations and raising capital for rapidly growing companies. Prior to joining Clinical Genomics, Roger served as Chief Executive Officer and Board Director of GlySure Limited, a leading UK based company specializing in continuous glucose monitoring (CGM) for patients under critical care. During his tenure, Moody strategically repositioned GlySure in the rapidly evolving home diabetes market while also establishing an economic value model for hospital adoption. Roger has also held leadership positions in a number of growth companies, including the role of Chief Financial Officer at Nanosphere, Inc and Medsn, Inc. where he served as CFO prior to becoming the Vice President, Business Development and then Chief Operating Officer. His extensive experience in managing rapid growth and delivering value to investors will be instrumental in achieving Clinical Genomics’ commercial objectives. Roger earned a Bachelor of Science in Finance from Syracuse University and a Master of Business Administration with an emphasis in Finance from the Graduate School of Business at the University of Chicago.
|
Robert Bruce
Vice President, Reimbursement
|
Mr. Bruce has over 25 years of experience advising and serving in senior management roles (CFO, COO, CEO, Director) for a range of private and public companies operating in highly-regulated industries, including healthcare, energy production, telecommunications and gaming. Prior to joining Clinical Genomics, he founded and led Oakmont Advisory Group, a financial and management consulting group serving a wide range of investors, lenders and shareholders in their efforts to improve operational and financial execution at client companies. Among his previous positions, he served as COO and VP of Reimbursement at Enterix and led the company’s efforts to secure regulatory approvals and reimbursement for the InSure® FIT test. He holds a BA in East Asian Studies from Princeton University (phi beta kappa; summa cum laude) and an MBA from the Yale University School of Management.
|
Michele Houldsworth
Vice President, Regulatory Affairs
|
Michele Houldsworth has deep experience in Quality Assurance specializing in system design and development for compliance in small to medium enterprises. She is a certified lead auditor of quality systems and medical devices and has hands on experience in all phases of product development from research to commercialization of medical devices and IVDs (Class II, III). Her experience includes successful achievement of ARTG listing and CE-marking, experience in technical file, design dossier and 510k file preparation for AU, EU, US and Chinese markets. Ms. Houldsworth is expert in process validation including sterilization and biocompatibility. BE MBiomedE (Mech; Honours Class I; University of New South Wales; 2007).
|
Susanne K. Pedersen, PhD
Vice President, Science and Innovation (CSO) and Co-Founder
|
Susanne Pedersen has deep commercial experience focused on biomarker discovery and validation including product concept to successful commercial launch. IVD assay expertise includes molecular diagnostics, proteomics, and immunoassays in esoteric pathology labs as well as point of care testing. Since 2010, her concentrated expertise has been in epigenetics and cell free DNA measurements for cancer detection. Dr. Pedersen is the Inventor of biomarker discovery patents and has a successful track record building cross-functional teams that meet commercial milestones including scale up. B.Sc. (Cell Biology; Southern University of Denmark, 1996); Ph.D. (Molecular Biology; Southern University of Denmark; 2000).
|